secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2022-12-02T23:59:59+00:00
Accession:  0001420720-22-000086
Event type: leadership
Sentiment:  neutral
Materiality: 0.70
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio CEO Thomas Isett resigns; interim office of CEO created with Lutz and Brenner
--------------------------------------------------------------------------------

- CEO Thomas Isett resigned effective Dec 1, 2022; no disagreement with strategy or policies.
- Isett will receive severance: 24 months base salary, pro-rata target bonus, plus COBRA coverage for 18 months.
- Board created Office of the CEO, with CFO Robert Lutz and CSO Dr. Martin Brenner filling the role.
- Leadership team reports to Board Chair William (Chip) Clark while search for new CEO continues.
- Isett remains employee until Dec 31, 2022; will assist with CDMO sale through March 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/0001420720-22-000086-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000142072022000086/ibio-20221201x8k.htm
  HTML page:      https://secwatch.observer/filing/0001420720-22-000086

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer